Guided Therapeutics’ Cervical Disease Detection Technology to be the Subject of a Presentation at the Upcoming ACOG Annual Meeting
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) today announced that its non-invasive and painless test for the early detection of cervical precancer, the LightTouch™, will be the subject of a presentation at The American College of Obstetricians and Gynecologists (ACOG) 59th Annual Clinical Meeting to be held April 30 - May 4, 2011 in Washington, DC.
The presentation, Study Results of a New Test for Cervical Dysplasia: Potential Impact on Patient Management, is scheduled to be presented by Dr. Leo B. Twiggs, professor in the Department of Obstetrics and Gynecology at the University of Miami, Miller School of Medicine on Monday, May 2nd from 2 p.m. to 4 p.m. Dr. Twiggs was a principal investigator in the pivotal clinical trial of the technology.
“This is the second major international scientific meeting to accept our technology for presentation to prominent thought leaders in the field of women’s health,” said Mark L. Faupel, CEO and president of Guided Therapeutics, Inc.
LightTouch, used as a triage test, would detect approximately 170,000 more women each year who have CIN2+, a diagnosis that places them at high risk for developing cancer of the cervix, while also reducing the number of unnecessary biopsies by more than 1 million, according to the study’s conclusions.
The technology is currently under Food and Drug Administration premarket approval review. Guided Therapeutics was recently awarded ISO 13485 certification for its quality system, a precursor for the CE mark required for sales in the European Union. The technology is also planned for a presentation at the EUROGIN scientific meeting in Lisbon in May, 2011.
About ACOG
Founded in 1951 in Chicago, Illinois, ACOG has over 52,000 members and is the nation's leading group of professionals providing health care for women. Now based in Washington, DC, it is a private, voluntary, nonprofit membership organization. For more information, visit www.acog.org.
About The LightTouch™
The LightTouch, which consists of a base unit and single-patient-use calibration disposable, scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics’ patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LightTouch test does not require laboratory analysis or a tissue sample, is designed to provide results immediately and eliminate costly unnecessary testing.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) is developing a rapid and painless testing platform for the early detection of disease based on its patented biophotonic technology that utilizes light to detect disease at the cellular level. The company’s first product, the LightTouch™, is a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial, with women at risk for cervical disease, the LightTouch was able to detect cervical cancer up to two years earlier than conventional modalities. LightTouch is designed to provide an objective result at the point-of-care, thereby improving the management of cervical disease. Guided Therapeutics has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett’s Esophagus using the LightTouch technology platform. For more information, visit: www.guidedinc.com. |
